New Delhi, September 17, 2022 (Globe Newswire) – The global Point of Care (PoC) infectious disease testing market is booming mainly due to the rapidly growing demand for PoC test kits to diagnose the increasing prevalence of infectious diseases, such as HIV, fluAnd the RSV, and Covid, among the world’s population.
Blue Wave Consultinga leading strategic advisory and market research firm, in its recent study, estimated the size of Global Point of Care (PoC) Infectious Disease Testing Market at US$1.4 billion in 2021. BlueWeave expects the global point-of-care infectious disease testing market to expand at an impressive CAGR of 17.4% between 2022 and 2028 to reach a size of US$4.22 billion by 2028. Key growth factors of the market include Expansion An increasing number of people worldwide are affected by a variety of infectious diseases, such as HIV, Covid, influenza, and RSV.
Global Point of Care (PoC) Infectious Disease Testing Market – Technology Advances
Due to the strong product portfolio and impressive distribution networks of large corporations in developed and developing countries, the infectious disease diagnostics market is becoming almost unified. Strategic alliances between key players in the sector and introduction of diagnostic products are expected to boost the companies’ growth and increase their market share. However, potential market opportunities allow a number of local competitors to enter in the coming years. By 2028, the market will be slightly fragmented as a result. For example, Precipio Inc. and ADS Biotech in a strategic alliance in July 2020 to develop a COVID-19 detection assay based on lateral flow immunoassay. It has received EUA approval to distribute the kits to physician laboratories, retail pharmacies, and consumers directly.
Global Point of Care (PoC) Infectious Disease Testing Market – High Demand
The prevalence of infectious diseases, including HIV, influenza and RSV, is on the rise globally, increasing the rate of patients being diagnosed. For example, the United Nations Program on HIV/AIDS (UNAIDS) estimated that 38 million people worldwide were diagnosed with HIV/AIDS in 2019. Additionally, a research study released by the World Health Organization indicates (WHO) reports that approximately 10 million people worldwide contracted tuberculosis in 2018. As a result, during the analysis period, the increased prevalence of infectious diseases would reinforce the need for PoC devices for their diagnosis, thus supporting market expansion.
Global Point of Care (PoC) Infectious Disease Testing Market – By Technology
Agglutination testing, flow testing/immunofocus assay, molecular diagnostics, and others are segments of the global Point of Care (PoC) infectious disease testing market based on this technology. In 2020, the lateral flow immunoassay market category represented an unbalanced market share. Faster diagnosis and access to test kits in decentralized environments are responsible for sovereignty. Additionally, the segment has grown as a result of more product launches as a result of COVID-19.
The increasing use of innovative tests, such as RT-PCR and ELISA in PoC test kits for infectious diseases, is expected to drive the molecular diagnostics market by 2028. In addition, an increase in FDA approvals is likely to accelerate segment revenue growth. Additionally, the flow test/immunofocus test market is expected to expand at a significant CAGR over the forecast period as more and more industry participants work to introduce advanced flow technology based kits in the international market. Besides, throughout the analysis period, the agglutination testing sector is expected to advance due to increased knowledge about the use of agglutination tests to diagnose infectious diseases.
Due to factors such as the presence of significantly large companies and a well-established healthcare system, the PoC infectious disease testing market is dominated by North America, with the United States accounting for the highest share of revenue. Moreover, the expected revenue share is supported by the introduction of technological developments in the United States. Meanwhile, due to the increase in R&D investment in patient-focused organizations in Japan and China, the Asia Pacific region (APAC) is expected to expand at the fastest rate. Furthermore, variables expected to drive regional success include the rapidly increasing burden of chronic infectious diseases and the presence of government initiatives aimed at encouraging early detection. Companies in the Asia Pacific region are focusing on creating new screenings. For example, in May 2017, One BioMed and the A*Star Genomics Institute in Singapore established a joint laboratory project to create molecular diagnostic assays. The goal of this collaboration is to create assays for the Asian market for clinical infectious disease diagnostics. Among these tests are tests for respiratory infections in children, mosquito-borne diseases, and drug-resistant tuberculosis.
Impact of COVID-19 on the global Point of Care Infectious Disease Testing Market
The COVID-19 pandemic has had a modest impact on pharmaceutical companies and research institutions focused on creating POC kits for COVID-19 diagnosis. The launch of advanced kits with fast turnaround times will accelerate market expansion during the analysis period. For example, BD (Becton, Dickinson and Company) reported in July 2020 that the FDA had approved the use of an Emergency Use Authorization (EUA) for a point-of-care SARS rapid diagnostic test for use with the widely used BD Veritor Plus system. . However, due to supply chain disruptions and the implementation of lockdown measures, demand and sales of diagnostic products related to infectious diseases, such as MRSA (methicillin-resistant Staphylococcus aureus), HIV (human immunodeficiency virus), and CDI (Clostridium difficile infection) have declined. In addition, revenue from companies, including Roche and Abbott, was affected by cuts in routine testing of diagnostic procedures for various disorders. However, the market is expected to recover quickly in the post-COVID-19 era.
Alere and Thermo Fisher Scientific Inc. and F. Hoffmann-La Roche Ltd. and Siemens Healthineers and BD & Co. and Chembio Diagnostics Inc. and Trinity Biotech, Cardinal Health, and Quest Diagnostics Inc. and Bio-Rad Labs Inc. and bioMérieux SA and Sight Diagnostics Ltd. and Gene POC, Trivitron Healthcare, and OJ-Bio Ltd. And Ortho-Clinical Diagnostics are leaders in the Global Point of Care (PoC) infectious disease testing market. The major players are currently creating strategic alliances with other established and emerging organizations. The objectives of the partnerships are to enhance market presence by creating a robust product portfolio that supports accurate diagnostics.
- Chembio Diagnostics, Inc., released the PoC COVID-19/Flu A&B Rapid Test in April 2021. Test results available in 15 minutes. Roche launched the Cobas SARS-CoV-2 Variant Set 1 test in March 2021. The test is designed to find forms of COVID-19 found in the UK, South Africa and Brazil.
|years considered||Historical data – 2018-2021|
|Base year – 2021|
|Estimated year – 2022|
|Forecast – 2022-2028|
|Covered facts||Revenue in millions of dollars|
|market coverage||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
|Product/service division||By technology, by disease, by end use, by region|
|The main players||Thermo Fisher Scientific Inc. and Alere Inc. and Calypte Biomedical Corporation and Chembio Diagnostic Systems, Inc. and Meridian Bioscience, Inc. and MedMira, Inc. and Trinity Biotech plc, Sekisui Diagnostics, OraSure Technologies, Inc. and Quidel Corporation.|
according to technology
- lateral flow
- Agglutination assays
- flow test
- Molecular Diagnostics
according to disease
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or infections associated with streptococcus
- Respiratory syncytial virus (RSV) POC
- Human papillomavirus (POC)
- Influenza / Influenza POC
- HCV POC
- MRSA POC
- Tuberculosis and drug-resistant tuberculosis (POC)
- HSV (Herpes simplex virus) POC
According to the end use
- Living healthcare facilities
- North Amarica
- Asia Pacific
- Latin america
- Middle East and Africa
Please see below for some new reports:
information about us
BlueWeave Consulting provides comprehensive Market Intelligence (MI) solutions to businesses regarding various online and offline products and services. We provide comprehensive market research reports by analyzing qualitative and quantitative data to enhance the performance of your business solutions. BWC has built its reputation from scratch by providing high quality input and nurturing long-term relationships with its clients. We are one of the most promising digital MI solutions company that provides agile assistance to make your business successful.
BlueWeave Consulting & Research Pvt. Ltd.
+1866658 6826 | +1 425 320 4776 | +44 1865 60 0662